Drug interactions during therapy with three major groups of antimicrobial agents

Bibliography

• JANKEL CA, FITTERMAN LK: Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf. (1993) 9:51-59.
   PubMed Web of Science ®Google Scholar
• GONZALEZ FJ: Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci. (1992) 13:346-352.
   PubMed Web of Science ®Google Scholar
• WILKINSON GR: Drug therapy: drug metabolism and variability among patients in drug response. N. Engl. J. Med. (2005) 352:2211-2221.
   PubMed Web of Science ®Google Scholar
• WACHER VJ, WU CJ, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. (1995) 13:129-134.
   PubMed Web of Science ®Google Scholar
• WACHER VJ, SILVERMAN JA, ZHANG Y, BENET LZ: Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. (1998) 87:1322-1330.
   PubMed Web of Science ®Google Scholar
• VON ROSENSTIEL NA, ADAM D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. (1995) 13:105-122.
   PubMed Web of Science ®Google Scholar
• STAHLMANN R, LODE H: Macrolides: tolerability and interactions with other drugs. Antiinfect. Drugs Chemother. (1996) 14:155-162.
   Google Scholar
• WESTPHAL JF: Macrolide-induced clinically relevant drug interactions with cytochrome P450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br. J. Clin. Pharmacol. (2000) 50:285-295.
   PubMed Web of Science ®Google Scholar
• PAI MP, GRACI DM, AMSDEN GW: Macrolide drug interactions: an update. Ann. Pharmacother. (2000) 34:495-513.
   PubMedGoogle Scholar
• ACKERMANN G, RODLOFF AC: Drugs of the 21st century: telithromycin (HMR 3647) – the first ketolide. J. Antimicrob. Chemother. (2003) 51:497-511.
   PubMed Web of Science ®Google Scholar
• WELLINGTON K, NOBLE S: Telithromycin. Drugs (2004) 64:1683-1694.
   PubMed Web of Science ®Google Scholar
• PRINCE RA, WING DS, WEINBERGER MM, HENDELES LS, RIEGELMAN S: Effect of erythromycin on theophylline kinetics. J. Allergy Clin. Immunol. (1981) 68:427-431.
   PubMedGoogle Scholar
• STEIGBIGEL NH: Macrolides and clindamycin. In: Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases (5th Edn). GL Mandell, JE Bennett, R Dolin (Eds), Churchill Livingstone, New York, NY, USA (2000):366-382.
   Google Scholar
• CHOUINARD G, LEFKO-SINGH K, TEBOUL E: Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem. Cell. Mol. Neurobiol. (1999) 19:533-552.
   PubMed Web of Science ®Google Scholar
• OLKKOLA KT, ARANKO K, LUURILA H et al.: A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. (1993) 53:298-305.
   PubMed Web of Science ®Google Scholar
• ARANKO K, LUURILA H, BACKMAN JT, NEUVONEN PJ, OLKKOLA KT: The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. Br. J. Clin. Pharmacol. (1994) 38:363-367.
   PubMed Web of Science ®Google Scholar
• YOUNG RA, GONZALEZ JP, SORKIN EM: Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs (1989) 37:8-41.
   PubMed Web of Science ®Google Scholar
• PETERS DH, CLISSOLD SP: Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs (1992) 44:117-164.
   PubMed Web of Science ®Google Scholar
• MARKHAM A, FAULDS D: Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs (1994) 48:297-326.
   PubMedGoogle Scholar
• YASUI N, OTANI K, KANEKO S, SHIMOYAMA R, OHKUBO T, SUGAWARA K: Carbamazepine toxicity induced by clarithromycin co-administration in psychiatric patients. Int. Clin. Psychopharmacol. (1997) 12:225-229.
   PubMedGoogle Scholar
• HIRATA S, IZUMI S, FURUKUBO T et al.: Interactions between clarithromycin and digoxin in patients with end-stage renal disease. Int. J. Clin. Pharmacol. Ther. (2005) 43:30-36.
   PubMed Web of Science ®Google Scholar
• RENGELSHAUSEN J, GOGGELMANN C, BURHENNE J et al.: Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. (2003) 56:32-38.
   PubMed Web of Science ®Google Scholar
• JACOBSON TA: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. (2004) 94:1140-1146.
   PubMed Web of Science ®Google Scholar
• TRIEU J, EMMETT L, PERERA C, THANAKRISHNAN K, VAN DER WALL H: Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy. Clin. Nucl. Med. (2004) 29:803-804.
   PubMedGoogle Scholar
• HONIG PK, WORTHAM DC, ZAMANI K, CANTILENA LR: Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. (1994) 7:148-156
   Google Scholar
• PETERS DH, FRIEDEL HA, MCTAVISH D: Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs (1992) 44:750-799.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN E: Comparative safety of the different macrolides. Int. J. Antimicrob. Agents. (2001) 18(Suppl. 1):S71-S76.
   PubMed Web of Science ®Google Scholar
• Ketek™ (telithromycin) tablets, Full Prescribing Information, Sanofi Aventis (2004).
   Google Scholar
• KOLILEKAS L, ANAGNOSTOPOULOS GK, LAMPADITIS I, ELEFTHERIADIS I: Potential interaction between telithromycin and warfarin. Ann. Pharmacother. (2004) 38:1424-1427.
   PubMedGoogle Scholar
• LONKS JR, GOLDMANN DA: Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis. (2005) 40:1657-1664.
   PubMed Web of Science ®Google Scholar
• LOMAESTRO BM, BAILIE GR: Absorption interactions with fluoroquinolones. 1995 update. Drug Saf. (1995) 12(5):314-333.
   PubMed Web of Science ®Google Scholar
• STAHLMANN R, LODE H: Safety overview. Toxicity, adverse effects, and drug interactions. In: The Quinolones (3rd Edn). V Andriole (Ed.), Academic Press, London, UK (2000):397-453.
   Google Scholar
• QAQISH R, POLK RE: Drug–drug interactions. In: Quinolone Antimicrobial Agents (3rd Edn). DC Hooper, E Rubinstein (Eds), ASM Press, Washington DC, USA (2003):133-146.
   Google Scholar
• HÖFFKEN G, BORNER K, GLATZEL PD, KOEPPE P, LODE H: Reduced enteral absorption of ciprofloxacin in the presence of antacids. Europ. J. Clin. Microbiol. (1985) 4:345.
   PubMedGoogle Scholar
• DEPPERMANN KM, LODE H: Fluoroquinolones. Interaction-profile during enteral absorption. Drugs (1993) 45(Suppl. 3):65-72.
   PubMedGoogle Scholar
• POLK RE, HEALY DP, SAHAI J, DRWAL L, RACHT E: Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother. (1989) 33:1841-1844.
   PubMed Web of Science ®Google Scholar
• GARRELTS JC, GODLEY PJ, PETERIE JD, GERLACH EH, YAKSHE CC: Sucralfate significantly reduces ciprofloxacin concentrations in serum. Antimicrob. Agents Chemother. (1990) 34:931-933.
   PubMed Web of Science ®Google Scholar
• STASS H, KUBITZA D: Profile of moxifloxacin drug interactions. Clin. Infect. Dis. (2001) 32(Suppl. 1):S47-S50.
   Google Scholar
• PALÙ G, VALISENA S, CIARROCCHI G, GATTO B, PALUMBO M: Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. USA (1992) 89:9671-9675.
   PubMed Web of Science ®Google Scholar
• FLOR S, GUAY DR, OPSAHL JA, TACK K, MATZKE GR: Effects of magnesium-aluminium hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob. Agents Chemother. (1990) 34:2436-2438.
   PubMedGoogle Scholar
• DEMBRY LM, FARRINGTON JM, ANDRIOLE VT: Fluoroquinolone antibiotics: adverse effects and safety profiles. Infect. Dis. Clin. Pract. (1999) 8:421-428.
   Google Scholar
• WIJNANDS WJ, VREE TB, VAN HERWAARDEN CL: The influence of quinolone derivatives on theophylline clearance. Br. J. Clin. Pharmacol. (1986) 22:677-683.
   PubMed Web of Science ®Google Scholar
• Tequin® (gatifloxacin) US package insert, Full Prescribing Information, Bristol-Myers Squibb (1999).
   Google Scholar
• Avelox® (moxifloxacin hydrochloride) tablets, USA package insert, Full Prescribing Information, Bayer Healthcare (1999).
   Google Scholar
• POLLAK PT, SLAYTER KL: Hazards of doubling phenytoin dose in the face of an unrecognized interaction with ciprofloxacin. Ann. Pharmacother. (1997) 31:61-64.
   PubMedGoogle Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330:263-272.
   PubMed Web of Science ®Google Scholar
• JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36:630-637.
   PubMed Web of Science ®Google Scholar
• HALL SD, THUMMEL KE, WATKINS PB et al.: Molecular and physical mechanisms of first pass extraction. Drug. Metab. Dispos. (1999) 27:161-166.
   PubMedGoogle Scholar
• PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):45-50.
   PubMedGoogle Scholar
• BACIEWICZ AM, BACIEWICZ FA: Ketoconazole and fluconazole interactions. Arch. Intern. Med. (1993) 153:1970-1976.
   PubMedGoogle Scholar
• ALBENGRES E, LOUET H, TILLEMENT JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. (1998) 18:83-97.
   PubMed Web of Science ®Google Scholar
• BLACK DJ, KUNZE KL, WIENKERS LC et al.: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug. Metab. Disp. (1996) 24:422-428.
   PubMed Web of Science ®Google Scholar
• OLKKOLA KT, AHONEN J, NEUVONEN PJ: The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. (1996) 82:511-516.
   PubMed Web of Science ®Google Scholar
• KATZ HI: Drug interactions of the newer oral antifungal agents. Br. J. Dermatol. (1999) 141:26-32.
   PubMed Web of Science ®Google Scholar
• RENGELSHAUSEN J, BANFIELD M, RIEDEL KD et al.: Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics. Clin. Pharmacol. Ther. (2005) 78:25-33.
   PubMed Web of Science ®Google Scholar
• KANDA Y, KAMI M, MATSUYAMA T et al.: Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol. Oncol. (1998) 16:33-37.
   PubMed Web of Science ®Google Scholar
• LIM SG, SAWYERR AM, HUDSON M, SERCOMBE J, POUNDER RE: Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. (1993) 7:317-321.
   PubMed Web of Science ®Google Scholar
• JARURATANASIRIKUL S, SRIWIRIYAJAN S: Effect of omeprazol on the pharmacokinetics of itraconazol. Eur. J. Clin. Pharmacol. (1998) 54:159-161.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE D, RYCKELYNK JP: Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. (1993) 24:10-27.
   PubMed Web of Science ®Google Scholar
• PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):51-55.
   PubMedGoogle Scholar
• POIRIER JM, CHEYMOL G: Optimization of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. (1998) 35:461-473.
   PubMed Web of Science ®Google Scholar
• BONAY M, JONVILLE-BERA AP, DIOT P, LEMARIE E, LAVANDIER M, AUTRET E: Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf. (1993) 9:309-311.
   PubMed Web of Science ®Google Scholar
• DUCHARME MP, SLAUGHTER RL, WARBASSE LH et al.: Itraconazole and hydroxyitraconazole serum concentrations are reduced more than ten fold by phenytoin. Clin. Pharmacol. Ther. (1995) 58:617-624.
   PubMed Web of Science ®Google Scholar
• PURKINS L, WOOD N, GHAHRAMANI P, LOVE ER, EVE MD, FIELDING A: Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):37-44.
   PubMed Web of Science ®Google Scholar
• BLUM RA, WILTON JH, HILLIGOSS DM et al.: Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. (1991) 49:420-425.
   PubMed Web of Science ®Google Scholar
• CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. (1998) 80:1-34.
   PubMed Web of Science ®Google Scholar
• VARHE A, OLKKOLA KT, NEUVONEN PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. (1994) 56:601-607.
   PubMed Web of Science ®Google Scholar
• KIVISTÖ KT, LAMBERG TS, KANTOLA T, NEUVONEN PJ: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. (1997) 63:348-354.
   Google Scholar
• LUURILA H, KIVISTÖ KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. (1998) 54:163-166.
   PubMed Web of Science ®Google Scholar
• BERTZ RJ, GRANNEMAN GR: Use of in vitro and in vivo data, to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. (1997) 32:210-258.
   PubMed Web of Science ®Google Scholar
• CAMPANA C, REGAZZI MB, BUGGIA I, MOLINARO M: Clinically significant drug interactions with cyclosporin. An update. Clin. Pharmacokinet. (1996) 30:141-179.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, SINGH N: Interactions between tacrolimus and antimicrobial agents. Clin. Infect. Dis. (1997) 25:1430-1440.
   PubMed Web of Science ®Google Scholar
• MCLACHLAN AJ, TETT SE: Effect of metabolic inhibitors on cyclosporin pharmacokinetics using a population approach. Ther. Drug Monit. (1998) 20:390-395.
   PubMed Web of Science ®Google Scholar
• JALAVA KM, OLKKOLA KT, NEUVONEN PJ: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. (1997) 61:410-415.
   PubMed Web of Science ®Google Scholar
• NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. (1996) 60:54-61.
   PubMed Web of Science ®Google Scholar
• AHONEN J, OLKKOLA KT, NEUVONEN PJ: Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. (1997) 51:415-419.
   PubMed Web of Science ®Google Scholar
• VARHE A, OLKKOLA KT, NEUVONEN PJ: Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br. J. Clin. Pharmacol. (1996) 42:465-470.
   PubMed Web of Science ®Google Scholar
• VARHE A, OLKKOLA KT, NEUVONEN PJ: Fluconazole but not terbinafine, enhances the effect of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. (1996) 41:319-323.
   PubMed Web of Science ®Google Scholar
• AHONEN J, OLKKOLA KT, NEUVONEN PJ: The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam. Clin. Pharmacol. (1996) 10:314-318.
   PubMed Web of Science ®Google Scholar
• GOMEZ DY, WACHER VJ, TOMLANOVICH SJ, HEBERT MF, BENET LZ: The effects of ketoconazole on intestinal metabolism and bioavailability of cyclosporin. Clin. Pharmacol. Ther. (1995) 58:15-19.
   PubMed Web of Science ®Google Scholar
• JALAVA KM, PARTANEN J, NEUVONEN PJ: Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. (1997) 19:609-613.
   PubMed Web of Science ®Google Scholar
• WANG EJ, LEW K, CASCIANO CN, CLEMENT RP, JOHNSON WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. (2002) 46:160-165.
   PubMed Web of Science ®Google Scholar
• BALAYSSAC D, AUTHIER N, CAYRE A, COUDORE F: Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol. Lett. (2005) 156:319-329.
   PubMed Web of Science ®Google Scholar
• CANAFAX DM, GRAVES NM, HILLIGOSS DM, CARLETON BC, GARDNER MJ, MATAS AJ: Interaction between cyclosporin and fluconazole in renal allograft recipients. Transplantation (1991) 51:1014-1018.
   PubMed Web of Science ®Google Scholar
• LOPEZ-GIL JA: Fluconazole-cyclosporin interaction: a dose dependent effect? Ann. Pharmacother. (1993) 27:427-430.
   PubMed Web of Science ®Google Scholar
• MANEZ R, MARTIN M, RAMAN D: Fluconazole therapy in transplant recipients receiving FK506. Transplantation (1994) 57:1521-1523.
   PubMed Web of Science ®Google Scholar
• ROMERO AJ, LE POGAMP P, NILSSON LG, WOOD N: Effect of voriconazole on the pharmacokinetics of cyclosporin in renal transplant patients. Clin. Pharmacol. Ther. (2002) 71:226-234.
   PubMed Web of Science ®Google Scholar
• GROLL AH, KOLVE H, EHLERT K, PAULUSSEN M, VORMOOR J: Pharmacokinetic interaction between voriconazole and cyclosporin A following allogeneic bone marrow transplantation. J. Antimicrob. Chemother. (2004) 53:113-114.
   PubMed Web of Science ®Google Scholar
• LOMAESTRO BM, PIATEK MA: Update on drug interactions with azole antifungal agents. Ann. Pharmacother. (1998) 32:915-928.
   PubMed Web of Science ®Google Scholar
• PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):24-29.
   PubMed Web of Science ®Google Scholar
• BOUCHER HW, GROLL AH, CHIOU CC, WALSH TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs (2004) 64:1997-2000.
   PubMed Web of Science ®Google Scholar